ABITEC Corporation is dedicated to the advancement of essential bioavailability enhancement and formulation development technology. ABITEC synthesizes and produces lipid based excipients to enhance bioavailability of poorly water soluble and poorly permeable molecules for the pharmaceutical industry.
ABITEC Corporation is dedicated to the advancement of essential bioavailability enhancement and formulation development technology. ABITEC synthesizes and produces lipid based excipients to enhance bioavailability of poorly water soluble and poorly permeable molecules for the pharmaceutical industry.
CAPMUL® Where Formulation Begins™
ABITEC has also expanded its portfolio of CAPMUL bioavailability enhancers which are medium-chain mono- and di-glycerides and propylene glycol esters. These functional lipid excipients act as solubilizers and emulsifiers in oral, topical, transdermal, and parenteral drug delivery systems. CAPMUL excipients are recognized as the ideal starting point when formulating BCS Class II & IV (poorly water soluble) and BCS Class III & IV (poorly permeable) molecules. Lipid based drug delivery systems may be formulated as liquid or semi-solid formulations for oral dosage forms, as well as creams and ointments for topical and transdermal applications.
CAPMUL may be used as a majority component in solubilization/emulsification formulations. Or whenever necessary, CAPMUL based formulations may be customized with the inclusion of CAPTEX medium-chain triglycerides and/or ACCONON® nonionic surfactants, added for enhanced bioavailability.
For further questions contact
Amanda Coulter
Manager: Marketing Research & Communications
acoulter@abiteccorp.com
ABITEC CORPORATION
501 W. 1ST Ave. | Columbus, OH 43215 USA | www.abiteccorp.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.